CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Idec today announced that enrollment is complete in the ASSURANCE trial, a long-term follow-up study which will assess up to 15 years of AVONEX® (interferon beta-1a) treatment in an effort to provide detailed data on the long term efficacy of the drug. ASSURANCE is a multi-center, open-label follow-up study of patients with relapsing multiple sclerosis (MS) treated with AVONEX or placebo for at least two years in the phase III pivotal trial. In the trial, 136 of a possible 172 patients were identified for this study at four major MS centers including: Cleveland Clinic Foundation, The State University of New York at Buffalo, Oregon Health and Science University and Georgetown University Medical Center.
